SHAKIRAT ODUKALE: Open Payments
NPI 1699337592 · LONG BRANCH, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,840 in 96 payments from 11 companies in 2025. Trend: 2023 $2,224 · 2024 $1,693 · 2025 $1,840
Food & beverage: $1,728Education: $111
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 18 | $346 |
| ABBVIE INC. | 31 | $338 |
| Neurocrine BioSciences, Inc. | 9 | $288 |
| E.R. Squibb & Sons, L.L.C. | 10 | $285 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $272 |
| Janssen Pharmaceuticals, Inc | 6 | $109 |
| Alkermes, Inc. | 5 | $84 |
| Otsuka America Pharmaceutical, Inc. | 4 | $71 |
| Braeburn Inc. | 1 | $17 |
| Lundbeck LLC | 1 | $15 |
Products named: VRAYLAR, INGREZZA, COBENFY, CAPLYTA, AUSTEDO XR, UZEDY, ARISTADA, INVEGA SUSTENNA.
Industry payments across NJ — which companies pay providers there.
